Microcap Ledger Seres Therapeutics, Inc. $MCRB
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Cambridge, MA
- Fiscal year end
- December 31
- Shares outstanding
- 9,941,261 [10-Q 2026-08-05]
What the company doesAI summary of filing
Seres Therapeutics is a clinical-stage biopharmaceutical company developing live biotherapeutic products (LBPs), which are consortia of bacteria designed for oral delivery to treat infectious diseases and inflammatory and immune conditions. The company previously developed and sold VOWST, the first FDA-approved orally administered microbiome therapeutic, to Nestlé Health Science in September 2024. Seres is currently advancing SER-155 for allogeneic hematopoietic stem cell transplantation patients and immune checkpoint-related enterocolitis, SER-603 for inflammatory bowel disease, and SER-147 for chronic liver disease, supported by its proprietary MbTx Platform for drug discovery. The company is pre-revenue from product sales, though it received milestone payments from the VOWST transaction, and operates in clinical development stage with ongoing funding needs. [10-K 2026-03-12]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $1.09M | −$15.33M | −$38.75M | $15.59M | [10-Q 2026-08-05] |
| FY ended Dec 2025 | $789.0K | $5.70M | $1.12M | $45.77M | [10-K 2026-03-12] |
| FY ended Dec 2024 | $0.00 | $136.0K | −$148.61M | $30.79M | [10-K 2026-03-12] |
- Quarterly cash burn
- −$19.38M
- Cash runway Estimate
- ~2.4 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-08-09 | 151,730,995 | [10-Q 2024-08-13] |
| 2024-11-08 | 170,738,069 | [10-Q 2024-11-13] |
| 2025-03-07 | 174,358,753 | [10-K 2025-03-13] |
| 2025-05-02 | 8,732,422 | [10-Q 2025-05-07] |
| 2025-08-01 | 8,754,570 | [10-Q 2025-08-06] |
| 2025-10-31 | 9,046,519 | [10-Q 2025-11-05] |
| 2026-03-06 | 9,586,298 | [10-K 2026-03-12] |
| 2026-08-03 | 9,941,261 | [10-Q 2026-08-05] |
- Shelf registration
- S-3 filed 2026-08-13; declared effective 2026-08-21 [S-3 2026-08-13]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2024-11-13. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2024-11-13 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2024-11-13] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-17 | Brady Kelly | sell | 64 | $4.55 | [4 2026-08-18] |
| 2026-08-17 | Shaff Eric D. | sell | 263 | $4.55 | [4 2026-08-18] |
| 2026-08-17 | Henn Matthew R | sell | 81 | $4.55 | [4 2026-08-18] |
| 2026-08-17 | Desrosier Thomas | sell | 82 | $4.55 | [4 2026-08-18] |
| 2026-08-15 | Brady Kelly | exercise | 181 | — | [4 2026-08-18] |
| 2026-08-15 | Shaff Eric D. | exercise | 722 | — | [4 2026-08-18] |
| 2026-08-15 | Henn Matthew R | exercise | 238 | — | [4 2026-08-18] |
| 2026-08-15 | Desrosier Thomas | exercise | 245 | — | [4 2026-08-18] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-13 | S-3 | Registration statement |
| 2026-08-05 | 10-Q | Quarterly report |
| 2026-08-05 | 8-K | Results of operations |
| 2026-08-04 | 8-K | Material agreement entered; Material agreement terminated |
| 2026-08-04 | 424B5 | Prospectus or prospectus supplement |
| 2026-07-08 | 8-K | Director or officer change; Shareholder vote results |
| 2026-07-08 | 8-K | Regulation FD disclosure; Other events |
| 2026-06-05 | 8-K | Material agreement entered; Regulation FD disclosure |
| 2026-06-01 | 8-K | Director or officer change |
| 2026-05-05 | 10-Q | Quarterly report |
| 2026-05-05 | 8-K | Results of operations |
| 2026-04-27 | DEF 14A | Proxy statement |
Alerts for $MCRB
Email me when Seres Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.